Glenmark Pharmaceuticals submits supplemental application for Metformin Hydrochloride
Glenmark Pharmaceuticals has submitted a supplemental application (ANDA078170) for Metformin Hydrochloride, which is currently under standard review by the FDA.
Asset / Drug
Drug and asset intelligence for Glenmark with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.